← back to search

Johannes Ridinger

German Cancer Research Center · DE
Area of research
Molecular Biology · Genetics
Research interest
Research interests include Histone Deacetylase Inhibitors Research, Glioma Diagnosis and Treatment, Epigenetics and DNA Methylation, and Ubiquitin and proteasome pathways.
h-index
19
citations
2,086
works
65
NIH funding
primary concept
email

Recent publications

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Journal of Neuro-Oncology 2023cited by 7position: middledoi
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Journal of Neuro-Oncology 2023cited by 3position: middledoi
Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout
Journal of the American Chemical Society 2022cited by 41position: middledoi
Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells
European Journal of Medicinal Chemistry 2022cited by 36position: middledoi
Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
International Journal of Molecular Sciences 2022cited by 36position: middledoi
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models
Cancers 2022cited by 30position: middledoi
First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement**
ChemBioChem 2022cited by 22position: middledoi
<scp>ERBB</scp> and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein
Molecular Oncology 2022cited by 10position: middledoi
Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras
Methods in molecular biology 2022cited by 8position: middledoi
Evaluation of Antitumor and On-Target Activity of HDAC Inhibitors with the Zebrafish Embryo Xenograft Model
Methods in molecular biology 2022cited by 4position: middledoi
First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement
ChemRxiv 2022cited by 2position: middledoi
Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells
ChemRxiv 2022cited by 1position: middledoi
Aza-SAHA Derivatives are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout
ChemRxiv 2022cited by 1position: middledoi
Identification of HDAC10 Inhibitors that Modulate Autophagy in Transformed Cells
ChemRxiv 2022cited by 0position: middledoi
Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
Cells 2021cited by 32position: middledoi
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
Cancers 2021cited by 14position: middledoi
Aza-SAHA Derivatives are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation
ChemRxiv 2021cited by 2position: middledoi
EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN <i>MYC</i>-AMPLIFIED MEDULLOBLASTOMA
Neuro-Oncology 2021cited by 0position: middledoi
Aza-SAHA Derivatives are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation
2021cited by 0position: middledoi
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma
Neuro-Oncology 2020cited by 70position: middledoi
Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors
ChemMedChem 2020cited by 37position: middledoi
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
Pharmaceuticals 2020cited by 30position: middledoi
First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Inhibitors of Neuroblastoma Cell Colony Growth That Increase Lysosome Accumulation
ChemRxiv 2020cited by 6position: middledoi
First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Inhibitors of Neuroblastoma Cell Colony Growth That Increase Lysosome Accumulation
ChemRxiv 2020cited by 1position: middledoi
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
Journal of Medicinal Chemistry 2019cited by 93position: middledoi
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Clinical Cancer Research 2018cited by 84position: middledoi
Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance
Scientific Reports 2018cited by 54position: firstdoi
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines
Archives of Toxicology 2018cited by 38position: middledoi
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
ChemRxiv 2018cited by 4position: middledoi
LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA
Neuro-Oncology 2018cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ina Oehme · German Cancer Research Center34 papers (2015–2023)Olaf Witt · St. Jude Children's Research Hospital15 papers (2016–2023)Nikolas Gunkel · German Cancer Research Center13 papers (2018–2022)Aubry K. Miller · German Cancer Research Center13 papers (2018–2022)David W. Christianson · University of Iowa Hospitals and Clinics12 papers (2020–2022)Manfred Jung · University of Freiburg10 papers (2018–2022)Till Milde · Children's Cancer Center10 papers (2016–2023) · 10 papers (2018–2022) · 9 papers (2020–2022)Corey J. Herbst‐Gervasoni · Drexel University9 papers (2020–2022)Raphael R. Steimbach · German Cancer Research Center9 papers (2018–2022) · 8 papers (2020–2022)Heike Peterziel · German Cancer Research Center8 papers (2017–2023)Magalie Géraldy · German Cancer Research Center7 papers (2018–2022) · 7 papers (2020–2022) · 7 papers (2022–2022)Peter Sehr · Heidelberg University7 papers (2018–2022)David Jones · Mayo Clinic in Florida6 papers (2016–2023)Olaf Witt · German Cancer Research Center6 papers (2015–2021)E Koeneke · German Cancer Research Center6 papers (2016–2018)